{"protocolSection": {"identificationModule": {"nctId": "NCT02192827", "orgStudyIdInfo": {"id": "647430-4"}, "organization": {"fullName": "University at Buffalo", "class": "OTHER"}, "briefTitle": "Use of Dexamethasone in Pediatric Asthma Exacerbations", "officialTitle": "Single Dose Dexamethasone is as Effective as Two Doses in Mild to Moderate Pediatric Asthma Exacerbations in the Emergency Department"}, "statusModule": {"statusVerifiedDate": "2023-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-04"}, "primaryCompletionDateStruct": {"date": "2018-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-07-11", "studyFirstSubmitQcDate": "2014-07-15", "studyFirstPostDateStruct": {"date": "2014-07-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-09-23", "resultsFirstSubmitQcDate": "2023-03-29", "resultsFirstPostDateStruct": {"date": "2023-03-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-03-29", "lastUpdatePostDateStruct": {"date": "2023-03-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Meghan Martin", "investigatorTitle": "Pediatric Emergency Medicine Attending Physician", "investigatorAffiliation": "University at Buffalo"}, "leadSponsor": {"name": "University at Buffalo", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare the efficacy of a single dose of dexamethasone vs. two doses of dexamethasone in mild and moderate asthma exacerbations pediatric patients.", "detailedDescription": "The emergency department (ED) physician will follow the standard asthma care path to manage a pediatric asthma patient whether the patient meets study criteria or not. Patients' legal guardian will be approached for consent if patient meets the study criteria. Once the consent is obtained, the patient will be randomized into one of the two study groups according to a randomization table generated by a statistician. The first group will receive a single dose of dexamethasone sodium phosphate injection (0.6 mg/kg with max of 16 mg) mixed with equivalent volume of cherry syrup given orally in the ED. The second group will receive a first dose of dexamethasone with cherry syrup (also 0.6 mg/kg with max of 16 mg) in the ED, and a second dose will be prescribed to the patient at home on the day following the ED visit. This dose will be the same dosage of dexamethasone, but may be a pill or liquid form. Patients will continue their previously prescribed asthma regimen and albuterol as needed. Children who vomit the steroids in the ED will be re-dosed. Children who vomit the steroid a second time will be excluded from the study.\n\n2. Data collection. Demographic information such as age, race, duration of asthma symptoms, number of previous hospitalizations, and current medication will be collected on an ED data collection form. Pertinent exam findings such as patient's vital signs, pulse oximetry, Pediatric asthma severity score (PAS), patient asthma severity self-assessment sheets (PSAS), and ED treatment will also be collected on an ED data collection form.\n\nAfter discharge from the ED, patients will be instructed to complete the PSAS on a daily basis for 5 days. The data will be documented on a home patient self-assessment sheet by the legal guardian. The investigators will train the legal guardians on how to complete the PSAS in the ED.\n\n3. Phone follow-up All patients will be contacted by phone by a research assistant 5 days after the ED visit. Information collected during the phone interview will include PSAS, unexpected visits to medical providers (ED, primary care or urgent care) for asthma symptoms, school days missed due to asthma exacerbation, length of time symptoms persisted, compliance with the recommended steroid regimen, vomiting, other side effects or medication administration problems caused by the steroids."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Pediatric", "Asthma", "Exacerbation", "Dexamethasone"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 318, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Single Dose Dexamethasone", "type": "EXPERIMENTAL", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once", "interventionNames": ["Drug: Dexamethasone Sodium Phosphate Injection"]}, {"label": "Two Dose Dexamethasone", "type": "EXPERIMENTAL", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.", "interventionNames": ["Drug: Dexamethasone Sodium Phosphate Injection"]}], "interventions": [{"type": "DRUG", "name": "Dexamethasone Sodium Phosphate Injection", "armGroupLabels": ["Single Dose Dexamethasone", "Two Dose Dexamethasone"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants Returning to Care Following Discharge From the Emergency Department", "description": "The investigators will determine if each patient had any unscheduled visits to the emergency room, urgent care or primary care physician.", "timeFrame": "5 days"}], "secondaryOutcomes": [{"measure": "Reported Number of Days Until Symptom Resolution", "description": "Will determine number of days to symptom resolution, including missed school days.", "timeFrame": "5 days"}], "otherOutcomes": [{"measure": "Reported Side Effects Experienced by Participants", "description": "The investigators will determine during phone follow up if patient experienced any side effects related to the Dexamethasone, including vomiting, mood swings, behavior changes, appetite changes, sweating or headache.", "timeFrame": "5 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Children aged 2 to 20 years, from all race and ethnicity groups, with a known history of asthma who present to the Emergency Department of Women and Children's Hospital of Buffalo with an acute exacerbation of mild or moderate asthma are potentially eligible for the study. Patients with severe asthma exacerbations will require intravenous steroid therapy, therefore, they will not be enrolled in the study. The investigators plan to enroll patients from winter of 2014 to fall 2016.\n\nHistory of asthma is defined by physician diagnosis of at least 1 prior episode of wheezing which responded to beta agonist medication.\n\nMild asthma is defined as: Pediatric Asthma Score (PAS) of 5 to 7; Moderate asthma is defined as: PAS of 8 to 11; Severe asthma is defined as: PAS of 12 or more.\n\nExclusion Criteria:\n\n* Children who have one of the following conditions will be excluded from the study: are less than 2 years of age, have signs of severe exacerbation (Pediatric Asthma Score of more than 11), have used oral steroids in the last 2 weeks, have chronic lung disease (e.g., cystic fibrosis), have been given IV solumedrol, or vomit two doses of dexamethasone in emergency department.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "2 Years", "maximumAge": "20 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Meghan E Martin, MD", "affiliation": "Johns Hopkins All Children's Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Women and Children's Hospital Of Buffalo", "city": "Buffalo", "state": "New York", "zip": "14222", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}]}, "referencesModule": {"references": [{"pmid": "26712860", "type": "BACKGROUND", "citation": "Akinbami LJ, Simon AE, Rossen LM. Changing Trends in Asthma Prevalence Among Children. Pediatrics. 2016 Jan;137(1):1-7. doi: 10.1542/peds.2015-2354. Epub 2015 Dec 28."}, {"pmid": "17983880", "type": "BACKGROUND", "citation": "National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. doi: 10.1016/j.jaci.2007.09.043. Erratum In: J Allergy Clin Immunol. 2008 Jun;121(6):1330."}, {"pmid": "1997850", "type": "BACKGROUND", "citation": "Chapman KR, Verbeek PR, White JG, Rebuck AS. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. N Engl J Med. 1991 Mar 21;324(12):788-94. doi: 10.1056/NEJM199103213241202."}, {"pmid": "12897291", "type": "BACKGROUND", "citation": "Rachelefsky G. Treating exacerbations of asthma in children: the role of systemic corticosteroids. Pediatrics. 2003 Aug;112(2):382-97. doi: 10.1542/peds.112.2.382."}, {"pmid": "8414819", "type": "BACKGROUND", "citation": "Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics. 1993 Oct;92(4):513-8."}, {"pmid": "9713398", "type": "BACKGROUND", "citation": "Zoorob RJ, Cender D. A different look at corticosteroids. Am Fam Physician. 1998 Aug;58(2):443-50."}, {"pmid": "22909281", "type": "BACKGROUND", "citation": "Cronin J, Kennedy U, McCoy S, An Fhaili SN, Crispino-O'Connell G, Hayden J, Wakai A, Walsh S, O'Sullivan R. Single dose oral dexamethasone versus multi-dose prednisolone in the treatment of acute exacerbations of asthma in children who attend the emergency department: study protocol for a randomized controlled trial. Trials. 2012 Aug 21;13:141. doi: 10.1186/1745-6215-13-141."}, {"pmid": "19801100", "type": "BACKGROUND", "citation": "Karaman M, Ilhan AE, Dereci G, Tek A. Determination of optimum dosage of intraoperative single dose dexamethasone in pediatric tonsillectomy and adenotonsillectomy. Int J Pediatr Otorhinolaryngol. 2009 Nov;73(11):1513-5. doi: 10.1016/j.ijporl.2009.06.001. Epub 2009 Jul 10."}, {"pmid": "11445789", "type": "BACKGROUND", "citation": "Qureshi F, Zaritsky A, Poirier MP. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. J Pediatr. 2001 Jul;139(1):20-6. doi: 10.1067/mpd.2001.115021."}, {"pmid": "18467673", "type": "BACKGROUND", "citation": "Greenberg RA, Kerby G, Roosevelt GE. A comparison of oral dexamethasone with oral prednisone in pediatric asthma exacerbations treated in the emergency department. Clin Pediatr (Phila). 2008 Oct;47(8):817-23. doi: 10.1177/0009922808316988. Epub 2008 May 8."}, {"pmid": "24515516", "type": "BACKGROUND", "citation": "Keeney GE, Gray MP, Morrison AK, Levas MN, Kessler EA, Hill GD, Gorelick MH, Jackson JL. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. Pediatrics. 2014 Mar;133(3):493-9. doi: 10.1542/peds.2013-2273. Epub 2014 Feb 10."}, {"pmid": "10831004", "type": "BACKGROUND", "citation": "Kelly CS, Andersen CL, Pestian JP, Wenger AD, Finch AB, Strope GL, Luckstead EF. Improved outcomes for hospitalized asthmatic children using a clinical pathway. Ann Allergy Asthma Immunol. 2000 May;84(5):509-16. doi: 10.1016/S1081-1206(10)62514-8."}, {"pmid": "18803532", "type": "BACKGROUND", "citation": "Chang AB, Clark R, Sloots TP, Stone DG, Petsky HL, Thearle D, Champion AA, Wheeler C, Acworth JP. A 5- versus 3-day course of oral corticosteroids for children with asthma exacerbations who are not hospitalised: a randomised controlled trial. Med J Aust. 2008 Sep 15;189(6):306-10. doi: 10.5694/j.1326-5377.2008.tb02046.x."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Excluded 10 Patients:\n\nPreviously enrolled into the study: 2 Admitted to the PICU (pediatric intensive care unit): 5 Required IV steroids in the Emergency Dept: 1 Steroid use within the last 2 weeks: 1 Excessive vomiting in the Emergency Dept: 1", "recruitmentDetails": "Patients presenting with asthma symptoms to a single pediatric emergency department", "groups": [{"id": "FG000", "title": "Single Dose Dexamethasone", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once\n\nDexamethasone Sodium Phosphate Injection"}, {"id": "FG001", "title": "Two Dose Dexamethasone", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.\n\nDexamethasone Sodium Phosphate Injection"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "154"}, {"groupId": "FG001", "numSubjects": "154"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "116"}, {"groupId": "FG001", "numSubjects": "116"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "38"}, {"groupId": "FG001", "numSubjects": "38"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "27"}]}, {"type": "Given additional steroids with admission", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "11"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Single Dose Dexamethasone", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once\n\nDexamethasone Sodium Phosphate Injection"}, {"id": "BG001", "title": "Two Dose Dexamethasone", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.\n\nDexamethasone Sodium Phosphate Injection"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "232"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "232"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "6.8", "spread": "3.9"}, {"groupId": "BG001", "value": "8.2", "spread": "4.4"}, {"groupId": "BG002", "value": "7.5", "spread": "4.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "232"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "92"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "72"}, {"groupId": "BG002", "value": "140"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "232"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "113"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "61"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "45"}]}]}]}, {"title": "Tobacco exposure in home", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "232"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "63"}]}]}]}, {"title": "Number of days with symptoms", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "days", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "232"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "3.6", "spread": "9.7"}, {"groupId": "BG001", "value": "3.1", "spread": "7.5"}, {"groupId": "BG002", "value": "3.3", "spread": "8.7"}]}]}]}, {"title": "Current use of asthma controller medication", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "232"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "54"}, {"groupId": "BG002", "value": "104"}]}]}]}, {"title": "Number of previous hospital admissions", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "admissions", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "232"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1.4", "spread": "1.9"}, {"groupId": "BG001", "value": "1.2", "spread": "2.5"}, {"groupId": "BG002", "value": "1.3", "spread": "2.2"}]}]}]}, {"title": "Pediatric Asthma Score before albuterol administered", "description": "Pediatric asthma Scores (based on respiratory rate by age, oxygen requirements, auscultation, retractions, dyspnea):\n\n5-7 Mild exacerbation 8-11 Moderate exacerbation 12-15 Severe exacerbation", "populationDescription": "PAS scores not available for all participants", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "PAS score", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "106"}, {"groupId": "BG001", "value": "107"}, {"groupId": "BG002", "value": "213"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "7.2", "spread": "1.8"}, {"groupId": "BG001", "value": "6.9", "spread": "1.5"}, {"groupId": "BG002", "value": "7.1", "spread": "1.6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants Returning to Care Following Discharge From the Emergency Department", "description": "The investigators will determine if each patient had any unscheduled visits to the emergency room, urgent care or primary care physician.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "5 days", "groups": [{"id": "OG000", "title": "Single Dose Dexamethasone", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once\n\nDexamethasone Sodium Phosphate Injection"}, {"id": "OG001", "title": "Two Dose Dexamethasone", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.\n\nDexamethasone Sodium Phosphate Injection"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "12"}]}]}]}, {"type": "SECONDARY", "title": "Reported Number of Days Until Symptom Resolution", "description": "Will determine number of days to symptom resolution, including missed school days.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "5 days", "groups": [{"id": "OG000", "title": "Single Dose Dexamethasone", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once\n\nDexamethasone Sodium Phosphate Injection"}, {"id": "OG001", "title": "Two Dose Dexamethasone", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.\n\nDexamethasone Sodium Phosphate Injection"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "3.5"}, {"groupId": "OG001", "value": "2.5", "spread": "3.4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Reported Side Effects Experienced by Participants", "description": "The investigators will determine during phone follow up if patient experienced any side effects related to the Dexamethasone, including vomiting, mood swings, behavior changes, appetite changes, sweating or headache.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "5 days", "groups": [{"id": "OG000", "title": "Single Dose Dexamethasone", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once\n\nDexamethasone Sodium Phosphate Injection"}, {"id": "OG001", "title": "Two Dose Dexamethasone", "description": "0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.\n\nDexamethasone Sodium Phosphate Injection"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"title": "No side effects", "categories": [{"measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "83"}]}]}, {"title": "Decreased Appetite", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Difficulty Sleeping", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Mood swings/Agitation", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Headache", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Multiple", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "18"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "5 days", "eventGroups": [{"id": "EG000", "title": "Single Dose Dexamethasone", "description": "This group was the standard arm and received one single dose of dexamethasone in the Emergency department", "deathsNumAffected": 0, "deathsNumAtRisk": 116, "seriousNumAffected": 0, "seriousNumAtRisk": 116, "otherNumAffected": 20, "otherNumAtRisk": 116}, {"id": "EG001", "title": "Two Doses of Dexamethasone", "description": "This group was the intervention group and received a dose of dexma", "deathsNumAffected": 0, "deathsNumAtRisk": 116, "seriousNumAffected": 0, "seriousNumAtRisk": 116, "otherNumAffected": 10, "otherNumAtRisk": 116}], "otherEvents": [{"term": "Decreased Appetite", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Reported decrease in appetite", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 116}]}, {"term": "Difficulty sleeping", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Reported difficulty sleeping", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Moodswing/Agitation", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Reported mood swings/agitation", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 116}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Meghan Martin", "organization": "Johns Hopkins all childrens hospital", "email": "mmart163@jhmi.edu", "phone": "9417373107"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2017-11-09", "uploadDate": "2022-11-21T12:04", "filename": "Prot_SAP_000.pdf", "size": 436484}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2017-11-09", "uploadDate": "2020-09-23T10:34", "filename": "ICF_001.pdf", "size": 251883}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M7796", "name": "Emergencies", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000003907", "term": "Dexamethasone"}, {"id": "C000018038", "term": "Dexamethasone acetate"}, {"id": "C000004180", "term": "Dexamethasone 21-phosphate"}, {"id": "C000101468", "term": "BB 1101"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000000932", "term": "Antiemetics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000005765", "term": "Gastrointestinal Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000018931", "term": "Antineoplastic Agents, Hormonal"}, {"id": "D000000970", "term": "Antineoplastic Agents"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M7102", "name": "Dexamethasone", "asFound": "ABP", "relevance": "HIGH"}, {"id": "M235549", "name": "Dexamethasone acetate", "asFound": "ABP", "relevance": "HIGH"}, {"id": "M199152", "name": "BB 1101", "asFound": "ABP", "relevance": "HIGH"}, {"id": "M342056", "name": "Dexamethasone 21-phosphate", "asFound": "ABP", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M4251", "name": "Antiemetics", "relevance": "LOW"}, {"id": "M8881", "name": "Gastrointestinal Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20966", "name": "Antineoplastic Agents, Hormonal", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ANeo", "name": "Antineoplastic Agents"}, {"abbrev": "AnEm", "name": "Antiemetics"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}